- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05023382
A Study of Teduglutide in Japanese People With Short Bowel Syndrome
Special Drug Use Investigation of Revestive Subcutaneous Injection 3.8 mg (All-case Surveillance)
The main aims of this study are to check for side effects from treatment with teduglutide (Revestive) and how well teduglutide controls symptoms of short bowel syndrome.
The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.
During the study, participants with short bowel syndrome will receive an injection of teduglutide just under the skin (subcutaneous) according to their clinic's standard practice. The study doctors will check for side effects from teduglutide for 36 months.
Study Overview
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Takeda Contact
- Phone Number: +1-877-825-3327
- Email: medinfoUS@takeda.com
Study Locations
-
-
-
Tokyo, Japan
- Recruiting
- Takeda selected site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- All participants in Japan who received teduglutide will be enrolled in this post marketing surveillance.
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Teduglutide 0.05 milligram per kilogram (mg/kg)
Participants will receive Teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily.
|
Teduglutide 0.05 mg/kg SC injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Events
Time Frame: Up to 36 months
|
An adverse event (AE) is any untoward or undesirable medical occurrence in a participant linked in time with the use of a pharmaceutical/ medicinal product.
They are not limited to the events with clear causal relationship with treatment with concerned drug.
An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
|
Up to 36 months
|
Number of Participants with Serious Adverse Events
Time Frame: Up to 36 months
|
A serious AE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability /incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.
|
Up to 36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from Baseline in Prescription Volume of Parenteral Nutrition Intravenous (PN/IV) Support
Time Frame: Baseline, 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation
|
Changes from baseline in prescription volume of PN/IV support prescribed by investigators to 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation will be reported.
|
Baseline, 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation
|
Percent Change from Baseline in Prescription Volume of PN/IV Support
Time Frame: Baseline, 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation
|
Percent change from baseline in prescription volume of PN/IV support to multiple timepoints (6, 12, 18, 24, 30, and 36 months) after teduglutide treatment initiation will be reported.
Percent change from baseline will be calculated as following; [prescription volume at each timepoint - prescription volume at baseline] / prescription volume at baseline * 100 (percent).
|
Baseline, 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation
|
Changes from Baseline in Dose of PN/IV Support
Time Frame: Baseline, 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation
|
Changes from baseline in actual dose of PN/IV support to 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation will be reported.
|
Baseline, 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation
|
Percent Change from Baseline of Dose in PN/IV Support
Time Frame: Baseline, 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation
|
Percent change from baseline in actual dose of PN/IV support to multiple timepoints (6, 12, 18, 24, 30, and 36 months) after teduglutide treatment initiation will be reported.
Percent change from baseline will be calculated as following; [actual dose at each timepoint - actual dose at baseline] / actual dose at baseline * 100 (percent).
|
Baseline, 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation
|
Percentage of Participants who Completely Wean off PN/IV Support
Time Frame: Baseline, 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation
|
Number of participants who completely wean off PN/IV support will be assessed.
|
Baseline, 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation
|
Crohn's Disease Activity Index (CDAI)
Time Frame: 36 months after teduglutide treatment initiation
|
CDAI score is calculated from the following 8 items: (a) Number of liquid or very soft stools; (b) Abdominal pain; (c) General wellbeing; (d) Extraintestinal complications; (e) Antidiarrhoeal drugs; (f) Abdominal mass; (g) Hematocrit; and (h) Body weight.
Scores of some items in CDAI are calculated based on patient diary.
Total range of score is more than 0. Higher score means more severe disease and especially severe disease was defined as a value of greater than 450.
|
36 months after teduglutide treatment initiation
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Study Director, Takeda
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TAK-633-5001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Short Bowel Syndrome
-
Marathon Pharmaceuticals, LLCWithdrawnShort Bowel Syndrome | Short Gut Syndrome | SBS | Short Gut | Short BowelUnited States
-
Central Hospital, Nancy, FranceBeaujon Hospital; Société Francophone Nutrition Clinique et MétabolismeUnknownSBS - Short Bowel SyndromeFrance
-
TakedaRecruitingShort Bowel Syndrome (SBS)Canada
-
GlyPharma TherapeuticsVectivBio AGCompletedSBS - Short Bowel SyndromeDenmark
-
TakedaCompletedShort Bowel Syndrome (SBS)Brazil
-
ShireRecruitingShort Bowel Syndrome (SBS)United States
-
Marathon Pharmaceuticals, LLCWithdrawnShort Bowel Syndrome | Short Gut Syndrome | SBS | Short GutUnited States
-
University of Texas Southwestern Medical CenterChildren's Hospital of PhiladelphiaEnrolling by invitationShort Gut SyndromeUnited States
-
Children's Hospital of PhiladelphiaUniversity of PennsylvaniaRecruiting
-
University of MiamiQOL Medical, LLCRecruitingShort Gut SyndromeUnited States
Clinical Trials on Teduglutide
-
ShireCompletedCrohn's DiseaseUnited States, Canada
-
ShireCompletedCrohn's DiseaseUnited States, Canada
-
ShireCompletedShort Bowel SyndromeUnited States, Denmark, France, Canada, Belgium, Netherlands, Poland, United Kingdom
-
ShireCompletedShort Bowel SyndromeUnited States, France, Germany, Canada, Netherlands, Poland, Denmark, Belgium, United Kingdom
-
ShireCompletedShort Bowel SyndromeUnited States, United Kingdom
-
ShireCompletedShort Bowel SyndromeUnited States, Canada, Finland, Belgium, Italy, United Kingdom, Germany
-
ShireNycomed Germany GmbHCompletedShort Bowel SyndromeSpain, United States, Canada, France, Denmark, Poland, Germany, Italy, United Kingdom
-
University Health Network, TorontoCompleted
-
ShireCompleted
-
ShireCompletedPharmacokinetics and Safety of Elevated DosesUnited States